Research Article

Recent Trends of Artificial Intelligence in Radiation Oncology: A Narrative Review of Prospective Studies

Applied Radiation Oncology — Vol. 14, Issue 3, pp. 1-13

DOI: 10.37549/ARO-D-25-0004

Published: August 1, 2025

Jas Virk, MD1, Simeng Zhu, MD2, Austin J. Sim, MD, JD2, Sung Jun Ma, MD2*

1 Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY

2 Department of Radiation Oncology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

* Corresponding author: Sung Jun Ma (SungJun.Ma@osumc.edu)

Abstract

In the past several decades, the delivery of radiation therapy has become increasingly intricate and precise. Such advancements were observed in conjunction with abundant multimodal data available for analysis; these include sophisticated diagnostic imaging, electronic health records, and digital pathology. The impact of artificial intelligence (AI) has become more prominent as numerous prior and ongoing prospective studies aim to integrate it into clinical care in radiation oncology. This review article provides an overview of such prospective studies and examines the role of AI in radiation therapy. By providing an understanding of recent trends in AI, we hope to contribute to improved patient outcomes and precision medicine in radiation oncology.

Keywords

AI, machine learning, deep learning, radiomics, large language model, multimodal

Introduction

Radiation therapy has progressed significantly over the past decades through such advances as stereotactic body radiation therapy (SBRT) for lung cancer1-3 and oligometastatic cancer,4-6 proton therapy for leptomeningeal metastasis,7 magnetic resonance imaging (MRI)-guided SBRT for prostate cancer,8 MRI-guided adaptive radiation therapy for pancreatic cancer,9 and adaptive radiation therapy for head and neck cancer.10 In addition, precision medicine has evolved to improve patient selection for various treatment approaches, including prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for prostate cancer, 11,12F-fluoromisonidazole PET for head and neck cancer, 13,14gallium DOTATATE PET for meningioma,15,16 21-gene recurrence scores for breast cancer,17,18 osimertinib after definitive chemoradiation for stage III epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer,19 and chimeric antigen receptor T-cell therapy.12

With such advancements in precision medicine, cancer genetics, and imaging modalities leading to abundant multimodal data available for health care professionals to interpret, artificial intelligence (AI) has emerged to leverage such data.20 For example, AI-based algorithms have greatly improved early diagnosis of breast cancer,21 pancreatic cancer,22 lung cancer,23 and skin cancer.24 Furthermore, generative AI has been shown to answer questions with more empathy than humans25 and to assist with medical documentation.26 In radiation oncology, several AI-related studies have emerged to minimize unplanned hospitalization27 and detect extranodal extension (ENE) in head and neck cancer.28,29 Since then, numerous reviews have summarized the role of AI in radiation oncology.30-33 However, none have focused on prospective studies incorporating AI into practice. In this review, we aimed to highlight the overview of recent trends in the application of AI in radiation oncology based on prior and ongoing prospective studies.

Methods

To identify relevant prospective studies on AI trends in radiation oncology, a literature search was conducted of the following electronic databases: PubMed, Medline, and Google Scholar. The following keywords were used: “radiation,” “radiation oncology,” and “artificial intelligence.” The search was limited to publications ranging from January 2002 to December 2024 and excluded retrospective studies, systematic reviews, case reports, conference abstracts, and expert opinion articles. Additional filters included utilizing only English language-written articles. Article titles and abstracts were then reviewed after initial screening, followed by full-text review prior to finalizing study inclusion.

Current clinical trials were searched utilizing the ClinicalTrials.gov website with the following keywords: “cancer,” “artificial intelligence,” and “radiation.” Studies that were completed or active (recruiting or not) were included, while those that were suspended or withdrawn were excluded. Trials were further categorized based on type, with only interventional studies included with no specific date range. When evaluating prospective studies or clinical trials, two reviewers determined the eligibility of such studies for inclusion.

Results

Of 4469 articles found through our literature search, 234 were initially identified as prospective studies. After reviewing abstracts and full texts to confirm their eligibility, 30 studies met our criteria, as shown in Table 1.

Table 1. Prior prospective studies
AUTHORSYEARDISEASE SITEPROSPECTIVE DATADATA TYPESMAIN FINDINGS
Zeleznik et al.342021BreastNot availableCT scanWith deep learning assistance, heart segmentation time was significantly reduced. Expert accuracy was comparable with deep learning-only segmentations.
Ma et al.352023BreastClinicalTrials.gov ID: NCT05609058CT scanDeep learning model identified the lead wire markers in the CT scan images, and the organ feature based on such markers was correlated with ipsilateral lung V20.
Dembrower et al.142023BreastScreenTrustCADMammogramReplacing one radiologist with AI for independent assessment of screening mammograms was non-inferior for cancer detection compared with reading by two radiologists.
Preetha et al.362021CNSCORE, CENTRIC, EORTC 26101MRI scanSynthetic postcontrast MRI scan based on pre-contrast MRI scanning using deep learning was feasible with no statistically significant difference in the contrast-enhancing tumor burden when compared to postcontrast MRI scanning.
Tsang et al.372024CNSNot availableCT scan94% of ML plans and 93% of manual plans were deemed to be clinically acceptable. ML plans were able to give 1 Gy less radiation to the normal brain than the manual plan. ML plans required 45 fewer minutes on average to create compared to manual plans.
George et al.382024CNSClinicalTrials.gov ID: NCT02336165MRI scanFirst on-treatment MRI features were correlated with overall and progression-free survival, while baseline MRI features were not.
Hong et al.272020GeneralSHIELD-RTClinical variablesAI-based algorithm based on routine electronic health record data triaged patients and reduced acute care visits during treatments.
Friesner et al.392022GeneralNCT02649569, NCT03102229, NCT03115398Daily step countsDaily step counts using an ML model were correlated with hospitalizations.
Kehayias et al.402024GeneralNot availableCT scanThe integration of Deep Learning On-Demand Assistant, an automated clinical platform to help with auto-segmentations and QA reporting using AI, into radiation oncology clinic workflow was feasible.
Natesan et al.412024GeneralSHIELD-RTClinical variablesHigh-risk patients identified by the AI-based algorithm experienced lower total medical costs from twice-weekly evaluations.
Wang et al.422022GIRTOG 0822CT scanAI-based algorithm using clinical variables, DVH, and radiomic features predicted pCR.
Wesdorp et al.432023GICAIRO5CT scanA DL autosegmentation model accurately segmented the liver and metastatic lesions.
Fremond et al.442023GYNPORTEC-1, PORTEC-2, PORTEC-3, TransPORTECWhole-slide images of H&E slidesA DL model predicted molecular classification.
Walker et al.452014Head/NeckNot availableCT scanAutosegmentation of organs at risk reduced the amount of time needed for segmentation, but expert oversight is still required for accuracy.
Men et al.462019Head/NeckRTOG 0522CT scanAI-based algorithm predicted the incidence of late xerostomia.
Sher et al.472021Head/NeckNot availableRadiation plansAI-based decision support tool improved the dose metrics for organs at risk.
Osapoetra et al.482021Head/NeckClinicalTrials.gov ID: NCT03908684Quantitative ultrasoundAI-based algorithm predicted treatment response of involved lymph nodes.
Mashayekhi et al.492023Head/NeckNot availableRadiation plansAI-based decision support tool improved uniformity of practice.
Kann et al.292023Head/NeckECOG/ACRIN 3311CT scanAI-based algorithm predicted extranodal extension more effectively than did radiologists.
Sher et al.502023Head/NeckINRT-AIRCT scanAI-based algorithm identified involved or suspicious lymph nodes, and there was no solitary elective nodal recurrence at 2 years without elective nodal irradiation.
Nicolae et al.512020ProstateNot availableUltrasoundAI-based radiation treatment planning reduced the time required for planning and was considered clinically acceptable.
McIntosh et al.522021ProstateNot availableRadiation plansAI-based radiation treatment planning reduced the time required for planning and was considered clinically acceptable.
Sanders et al.532022ProstateNot availableMRI scanAutosegmentation of prostate and organs at risk was considered clinically feasible.
Thomas et al.542022ProstateClinicalTrials.gov ID: NCT03238170Radiation plansAI-based algorithm predicted those who would benefit from rectal spacer placement.
Johnsson et al.552022ProstateOSPREYPSMA PET/CTAI-based algorithm identified potential lesions and autosegmented organs.
Esteva et al.562022ProstateNRG/RTOG 9202, 9413, 9910, 0126Whole slide images of H&E slidesAI-based algorithm risk stratified and identified patients with poor prognoses.
Spratt et al.572023ProstateNRG/RTOG 9202, 9413, 9910, 0126, 9408Whole slide images of H&E slidesAI-based algorithm predicted patients who would benefit from androgen deprivation therapy.
Ross et al.582024ProstateNRG/RTOG 9902Whole slide images of H&E slidesAI-based algorithm risk stratified and identified patients with poor prognoses.
Spratt et al.592024ProstateNRG/RTOG 9202, 9408, 9413, 9910, 9902, 0521Whole slide images of H&E slidesAI-based algorithm risk stratified and identified patients with poor prognoses.
Wong et al.602020Prostate/Head Neck/CNSNot availableCT scanAI-based algorithm reduced the time required for contouring and autosegmented at-risk organs and target volumes.

AI in Prostate Cancer

AI has been investigated extensively to improve outcomes of patients with prostate cancer. In earlier years, because of substantial interobserver disagreements in Gleason grade among pathologists,61,62 AI-assisted digital pathology algorithms based on whole-slide images of hematoxylin and eosin-stained tissues were developed to improve reproducibility in determining Gleason grade,63 which were recognized by Food and Drug Administration and other regulatory agencies.63

Beyond assessment of Gleason grades, the role of digital pathology has been investigated in radiation oncology. Esteva et al. initially leveraged five NRG Oncology phase III randomized clinical trials (NRG/RTOG 9202, 9413, 9910, 0126, and 9408) that included patients with localized prostate cancer who received radiation with or without androgen-deprivation therapy (ADT).56 Self-supervised, prognostic, and multimodal AI architecture was developed based on clinical variables (age, Gleason primary and secondary grades, T stage, and baseline PSA) from over 5600 patients and imaging features from over 16 000 histopathology slides.56 Across all endpoints, AI outperformed the National Comprehensive Cancer Network (NCCN) risk-stratification tool by 9.2%-14.6% for relative improvements in area under the receiver operating characteristic curve (AUC).56

With its early success, digital pathology was further investigated for its predictive ability. Spratt et al. utilized four NRG Oncology phase III clinical trials (NRG/RTOG 9202, 9413, 9910, 0126) to develop a similar multimodal AI architecture and validated its performance on the NRG/RTOG 9408 dataset.57 The primary objective of this study was to identify a subgroup of patients who might benefit from adding ADT to radiation.57 The development cohort comprised over 2000 patients, with the majority having intermediate-risk prostate cancer, while the validation cohort consisted of over 1500 patients, with more than half having intermediate-risk prostate cancer.57 Over a third of patients in the validation cohort were classified as predictive model-positive, demonstrating an absolute improvement of 10% by adding ADT for distant metastasis-free survival and prostate-cancer-specific survival at 15 years.57 However, no differential treatment benefits were identified between predictive model subgroups for metastasis-free survival and overall survival.57 Spratt et al. performed a separate analysis using six NRG Oncology clinical trials (NRG/RTOG 9202, 9408, 9413, 9910, 9902, 0521), validating the multimodal AI algorithm as prognostic for distant metastasis and prostate cancer-specific mortality among patients with high-risk prostate cancer.59 Subsequently, the NCCN Guideline for prostate cancer included ArteraAI Prostate as the first AI-based tool with prognostic and predictive benefits from ADT among patients with localized prostate cancer.64

AI in Head and Neck Cancer

Other malignancies targeted by extensive research in AI are head and neck cancers, especially with respect to radiomics. For example, ENE is a known adverse feature associated with poor locoregional control.65,66 However, ENE identification has been largely based on pathologic evaluation, since radiographic determination has been inconsistent.67-69 As a result, 24%-31% of patients with p16+ head and neck cancer receive trimodality therapy.70,71 To reduce this knowledge gap, Kann et al. developed a deep-learning (DL) algorithm based on 270 patients from a single institution with over 650 lymph nodes segmented.72 The model predicted ENE and nodal metastasis with an AUC of 0.91 for both endpoints.72 Based on such early success, Kann et al. utilized validation datasets of 82 patients with 130 lymph nodes segmented from Mount Sinai Hospital and 62 patients with 70 lymph nodes segmented from The Cancer Genome Atlas imaging data through The Cancer Imaging Archive.28 The DL model predicted ENE with an AUC of 0.84-0.90 on these validation datasets, outperforming diagnostic radiologists and improving interobserver agreement among these radiologists.28 Owing to the small sample size of p16-positive oropharyngeal cancer in these retrospective datasets,28 further validation was performed using a multicenter phase II clinical trial, ECOG-ACRIN 3311.29 The DL model was retrained using three retrospective datasets as mentioned previously, ultimately identifying 178 patients from ECOG-ACRIN 3311 with 313 manually segmented lymph nodes.29 It had an AUC of 0.86 for the identification of ENE, outperforming four radiologists, with a limitation of node level segmentation required prior to independent testing.29

Another evolving paradigm for treatment de-escalation among patients with head and neck cancer is to reduce treatment volume. Several phase II clinical trials and a large retrospective study demonstrated the feasibility of reducing the dose of elective nodal irradiation to 30-40 Gy.73-75 To omit elective nodal irradiation, colleagues from the University of Texas Southwestern Medical Center evaluated several DL models using 129 patients and over 700 lymph nodes segmented with AUC of 0.88-0.98,76-78 comparable to the AUC of 0.91 from the study by Kann et al.72 Subsequently, Sher et al. incorporated this model in the prospective phase II INRT-AIR trial.50 Of 67 patients with nonmetastatic head and neck cancer who underwent definitive radiation or chemoradiation, an average of 31 lymph nodes per patient were evaluated by the DL model, determining that approximately 10% were involved.50 At a median follow-up of 33 months, overall and progression-free survival at 2 years were favorable at 91% and 82%, respectively.50 One patient with heavy marijuana use had an out-of-field elective nodal recurrence with concurrent distant metastasis, but the study otherwise found favorable quality of life outcomes with no solitary elective nodal failure.50

AI in Supportive Care

In addition to improving oncologic outcomes, another area incorporating AI is the effort to reduce acute care visits, such as emergency department visits and unplanned hospitalizations. Predicting such events has been investigated among patients without a cancer diagnosis.79-82

In radiation oncology, Hong et al. initially developed a machine learning (ML) model based on nearly 7000 patients with over 8000 treatment courses at a single institution; this model included variables such as baseline demographics, disease and treatment characteristics, prior acute care visits, laboratory values, and recent vital signs.83 Internal validation demonstrated an AUC of 0.80 for the ML model in predicting acute care visits.83 Subsequently, Hong et al. performed the SHIELD-RT single-institution, prospective quality improvement study.27 This model was utilized to identify high-risk patients, who were defined as having more than a 10% risk of acute care visits, and randomized them to twice-weekly on-treatment visits versus standard of care.27 Of nearly 1000 treatment courses, 311 were evaluated as high-risk courses, with the majority of patients having gastrointestinal cancer or primary brain cancer.27 The ML model had a favorable performance with an AUC of 0.82 for triaging patients to high- versus low-risk for acute care visits, and fewer than 3% of low-risk patients had acute care visits.27 Twice-weekly evaluation led to a reduction from 22% to 12% of acute care visits during radiation therapy, the primary endpoint of this study.27 Furthermore, a post-hoc economic analysis showed that such a reduction in acute care visits translated to lower health care costs.41

Ongoing Clinical Trials

Table 2 consists of a list of ongoing clinical trials that incorporate AI. In particular, a multimodal AI risk-stratification developed by Spratt et al.57,59 has been incorporated into two such clinical trials. The HypoElect study (ClinicalTrials.gov ID: NCT06582446) is a single-arm phase II clinical trial that consists of patients with NCCN high-risk, multimodal AI high-risk prostate cancer and is evaluating the role of whole-pelvis radiation in five fractions with radiation dose escalation using brachytherapy and two years of ADT. The second study is the (ClinicalTrials.gov ID: NCT06772441), a single-arm, phase II HypoPro clinical trial comprising patients with NCCN high-risk, multimodal AI low-/intermediate-risk prostate cancer and is investigating SBRT in combination with brachytherapy and concurrent ADT. Additionally, while most ongoing clinical trials leverage AI for adaptive radiation therapy (Table 2), another noteworthy study is a randomized clinical trial by researchers at the University of Hong Kong (ClinicalTrials.gov ID: NCT06636188). It is the first prospective study incorporating a chatbot, Digi-Coach, to help reduce physical and psychological distress versus usual nursing care among patients with head and neck cancer.

Table 2. Ongoing Prospective Studies
CLINICAL TRIALCLINICAL TRIALS.GOV IDSTART DATEESTIMATED END DATESTUDY DESIGNROLE OF AIStatusDisease site
Artificial IntelligenceI for Prostate Cancer Treatment PlanningNCT0444177520202022ObservationalImprove consistency and quality of radiation treatment plans.CompletedProstate
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT0451371720202033InterventionalRadiation therapy quality assurance using an AI algorithm.RecruitingProstate
ARtificial Intelligence for Gross Tumor Volume Segmentation (ARGOS)NCT0577506820212024ObservationalAutosegmentation of GTV on CT scan.Active, not recruitingThoracic
Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients (KIVAL-KHT)NCT0519265520212026ObservationalAnalysis of diagnostic imaging and clinical and histopathological data to predict outcomes.RecruitingHead/Neck
AI for Head Neck Cancer Treated With Adaptive RadioTherapy (RadiomicART)NCT0508153120212024InterventionalAnalysis of diagnostic imaging to predict outcomes and toxicities.RecruitingHead/Neck
PostRadiotherapy MRI-based AI System to Predict Radiation Proctitis for Pelvic CancersNCT049189922021TBDObservationalAnalysis of post-radiation MRI scan to predict proctitis.Unknown statusGeneral
Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs At RiskNCT0578752220222024ObservationalAutosegmentation of organs at risk on CT scan.CompletedThoracic
Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy DeviceNCT0509628620222022InterventionalSimulation-free workflow using a semi-automated planning based on AI.CompletedCNS
The Impact of Radiotherapy on Oligometastatic CancerNCT0593387620222037ObservationalAnalysis of clinical data, medical images, and biological samples to predict who will benefit from radiation to oligometastatic sites.RecruitingGeneral
Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT TrialNCT0533890520222027InterventionalAnalysis of clinical data to identify high-risk patients who will benefit from symptom surveillanceRecruitingHead/Neck
Artificial Intelligence in CNS Radiation Oncology (AI-RAD)NCT0603639420232028ObservationalAutosegmentation of tumor and organs at risk, use radiomics to predict toxicities and outcomes.Active, not recruitingCNS
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI StudyNCT0580218620232026InterventionalAI to guide radiation dose for primary lung cancer and lung metastases.RecruitingThoracic
Adaptive Radiation in Anal CancerNCT0583839120232025InterventionalAdaptive radiation using AI.RecruitingGI
Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning versus Standard Radiation Treatment PlanningNCT0597988320232026Interventional-Phase IIIAI-assisted radiation treatment planning.RecruitingHead/Neck
MR-guidance in Chemoradiotherapy for Cervical Cancer (AIM-C1)NCT0614276020232026InterventionalAdaptive radiation using AI.RecruitingGU
Daily-Adaptive Stereotactic Body Radiation Therapy for Biochemically Recurrent, Radiologic Apparent Prostate Cancer After Radical ProstatectomyNCT0594682420232028Interventional-Phase IIAdaptive radiation using AI.RecruitingProstate
Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung CancerNCT0578584520232026InterventionalAdaptive radiation using AI.RecruitingThoracic
A Chatbot to Reduce Physical and Psychological Distress of Patients With Head and Neck Cancer Undergoing RadiotherapyNCT0663618820242027InterventionalAI-based patient navigator chatbot to reduce physical and psychological distress.Active, not recruitingHead/Neck
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow (GLADIATOR)NCT0649248620242028Interventional-Phase IIAdaptive radiation using AI.Not yet recruitingCNS
AI as an Aid for Weekly Symptom Intake in RadiotherapyNCT0652518120242024InterventionalMedical documentation for on-treatment visits to improve accuracy and efficiency.Not yet recruitingGeneral
A phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery (BC-AIO)NCT0668645920242027Interventional-Phase IIAutosegmentation and radiation treatment planning.Not yet recruitingBreast
Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment PlanningNCT0620011620242026ObservationalAutosegmentation.RecruitingGeneral
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma (OART)NCT0651613320242030Phase III Clinical TrialAdaptive radiation using AI.RecruitingHead/Neck
One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors (ONE STOP)NCT0623651620242025Phase III Clinical TrialAdaptive radiation using AI.RecruitingThoracic
Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial) (HypoElect)NCT0658244620242027Interventional-Phase IIPatient selection and risk stratification.RecruitingProstate
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial) (HypoPro)NCT0677244120242027InterventionalPatient selection and risk stratification.RecruitingProstate
RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3 (RADPAINT-3)NCT0629790220242030InterventionalAnalysis of blood samples to predict tumor response and toxicities.RecruitingHead/Neck
Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma (ARTPLAN-GLIO)NCT0665702720252027ObservationalAnalysis of MRI scans to evaluate the extent of tumor infiltration.Not yet recruitingCNS
Locally Optimised Contouring With AI Technology for Radiotherapy (LOCATOR)NCT0654659220252029InterventionalAutosegmentation.Not yet recruitingGeneral

Limitations

Limitations of this study include its utilization only of prospective studies while excluding retrospective studies and other types of journal articles. The rationale for this decision is that several published reviews already incorporate retrospective studies to discuss the role of AI in radiation oncology.30-33 As a result, however, bias may be introduced toward reporting studies from major cancer centers with access to experts with significant AI technical skills. Subsequently, results from these prospective studies may not be generalizable to or implemented in smaller community cancer centers without access to such AI expertise. For instance, significant barriers hindered implementation of the SHIELD-RT trial process; these included labor-intensive, manual verification of treatment course data for each eligible patient, generating and verifying AI predictions by multiple investigators for each enrolled patient, and manually deploying clinical alerts for treating physicians and enrolled patients to ensure that the intervention was completed on time per protocol.84 In addition, discussion of commercially available technologies is beyond the scope of this review. These have been comprehensively discussed by NRG Oncology in its summary of the roles of commercial products in adaptive radiation, autosegmentation, treatment planning, and clinical trial development.85-88 Lastly, despite our efforts to include prospective AI data, we may have inadvertently excluded other relevant studies from our review. Further studies are warranted to capture the growing complexity of AI and its impact in radiation oncology.

Conclusion

Radiation oncology is poised to be influenced substantially by AI in the coming decades. Emerging AI tools will streamline radiation treatment planning and adaptive radiation, guide treatment recommendations by improving patient selection based on digital pathology and radiomics, and tailor supportive care to reduce acute care visits. As a result, such efforts will translate to further progress in radiation oncology and patient outcomes.

References

  1. Bezjak A, Paulus R, Gaspar L. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. J Clin Oncol. 2019;37(15):1316-1325. doi:10.1200/JCO.18.00622.
  2. Singh A, Gomez-Suescun J, Stephans K. One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys. 2019;105(4):752-759. doi:10.1016/j.ijrobp.2019.08.019.
  3. Videtic G, Hu C, Singh A. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015;93(4):757-764. doi:10.1016/j.ijrobp.2015.07.2260.
  4. Deek M, Van der Eecken K, Sutera P. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40(29):3377-3382. doi:10.1200/JCO.22.00644.
  5. Palma D, Olson R, Harrow S. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830-2838. doi:10.1200/JCO.20.00818.
  6. Tsai C, Yang J, Shaverdian N. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171-182. doi:10.1016/S0140-6736(23)01857-3.
  7. Yang J, Wijetunga N, Pentsova E. Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J Clin Oncol. 2022;40(33):3858-3867. doi:10.1200/JCO.22.01148.
  8. Kishan A, Ma T, Lamb J. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol. 2023;9(3):365-373. doi:10.1001/jamaoncol.2022.6558.
  9. Chuong M, Lee P, Low D. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study. Radiother Oncol. 2024;191:110064. doi:10.1016/j.radonc.2023.110064.
  10. Castelli J, Thariat J, Benezery K. Weekly adaptive radiotherapy vs standard intensity-modulated radiotherapy for improving salivary function in patients with head and neck cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(8):1056-1064. doi:10.1001/jamaoncol.2023.1352.
  11. Hofman M, Lawrentschuk N, Francis R. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (propsma): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7.
  12. June C, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73. doi:10.1056/NEJMra1706169.
  13. Lee N, Sherman E, Schöder H. Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma. J Clin Oncol. 2024;42(8):940-950. doi:10.1200/JCO.23.01308.
  14. Dembrower K, Crippa A, Colón E. Artificial intelligence for breast cancer detection in screening mammography in sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health. 2023;5(10). doi:10.1016/S2589-7500(23)00153-X.
  15. Perlow H, Nalin A, Handley D. A prospective registry study ofGa-DOTATATE PET/CT incorporation into treatment planning of intracranial meningiomas 68. Int J Radiat Oncol Biol Phys. 2024;118(4):979-985. doi:10.1016/j.ijrobp.2023.10.014.
  16. Perlow H, Raleigh D, Wang T. Consensus radiation treatment planning guidelines using (68)Ga-DOTATATE PET/CT for resected meningiomas. Int J Radiat Oncol Biol Phys. 2025;122(1):150-158. doi:10.1016/j.ijrobp.2024.12.003.
  17. Kalinsky K, Barlow W, Gralow J. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336-2347. doi:10.1056/NEJMoa2108873.
  18. Sparano J, Gray R, Makower D. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121. doi:10.1056/NEJMoa1804710.
  19. Lu S, Kato T, Dong X. osimertinib after chemoradiotherapy in stage III EGFR -mutated NSCLC. N Engl J Med. 2024;391(7):585-597. doi:10.1056/NEJMoa2402614.
  20. Howell M, Corrado G, DeSalvo K. Three epochs of artificial intelligence in health care. JAMA. 2024;331(3):242-244. doi:10.1001/jama.2023.25057.
  21. McKinney S, Sieniek M, Godbole V. International evaluation of an AI system for breast cancer screening. Nature. 2020;577(7788):89-94. doi:10.1038/s41586-019-1799-6.
  22. Cao K, Xia Y, Yao J. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Nat Med. 2023;29(12):3033-3043. doi:10.1038/s41591-023-02640-w.
  23. Ardila D, Kiraly A, Bharadwaj S. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med. 2019;25(6):954-961. doi:10.1038/s41591-019-0447-x.
  24. Liu Y, Jain A, Eng C. A deep learning system for differential diagnosis of skin diseases. Nat Med. 2020;26(6):900-908. doi:10.1038/s41591-020-0842-3.
  25. Ayers J, Poliak A, Dredze M. Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum. JAMA Intern Med. 2023;183(6):589-596. doi:10.1001/jamainternmed.2023.1838.
  26. Nayak A, Alkaitis M, Nayak K. Comparison of history of present illness summaries generated by a chatbot and senior internal medicine residents. JAMA Intern Med. 2023;183(9):1026-1027. doi:10.1001/jamainternmed.2023.2561.
  27. Hong J, Eclov N, Dalal N. System for high-intensity evaluation during radiation therapy (SHIELD-RT): a prospective randomized study of machine learning-directed clinical evaluations during radiation and chemoradiation. J Clin Oncol. 2020;38(31):3652-3661. doi:10.1200/JCO.20.01688.
  28. Kann B, Hicks D, Payabvash S. Multi-institutional validation of deep learning for pretreatment identification of extranodal extension in head and neck squamous cell carcinoma. J Clin Oncol. 2020;38(12):1304-1311. doi:10.1200/JCO.19.02031.
  29. Kann B, Likitlersuang J, Bontempi D. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023;5(6). doi:10.1016/S2589-7500(23)00046-8.
  30. Huynh E, Hosny A, Guthier C. Artificial intelligence in radiation oncology. Nat Rev Clin Oncol. 2020;17(12):771-781. doi:10.1038/s41571-020-0417-8.
  31. Kalsi S, French H, Chhaya S. The evolving role of artificial intelligence in radiotherapy treatment planning-a literature review. Clin Oncol (R Coll Radiol). 2024;36(10):596-605. doi:10.1016/j.clon.2024.06.005.
  32. Kawamura M, Kamomae T, Yanagawa M. Revolutionizing radiation therapy: the role of AI in clinical practice. J Radiat Res. 2024;65(1):1-9. doi:10.1093/jrr/rrad090.
  33. Parkinson C, Matthams C, Foley K, Spezi E. Artificial intelligence in radiation oncology: a review of its current status and potential application for the radiotherapy workforce. Radiography (Lond). 2021;27 Suppl 1:S63-S68. doi:10.1016/j.radi.2021.07.012.
  34. Zeleznik R, Weiss J, Taron J. Deep-learning system to improve the quality and efficiency of volumetric heart segmentation for breast cancer. NPJ Digit Med. 2021;4(1). doi:10.1038/s41746-021-00416-5.
  35. Ma L, Yang Y, Ma J. Correlation between AI-based CT organ features and normal lung dose in adjuvant radiotherapy following breast-conserving surgery: a multicenter prospective study. BMC Cancer;23(1):1085. doi:10.1186/s12885-023-11554-2.
  36. Jayachandran Preetha C, Meredig H, Brugnara G. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. Lancet Digit Health. 2021;3(12). doi:10.1016/S2589-7500(21)00205-3.
  37. Tsang D, Tsui G, Santiago A. A prospective study of machine learning-assisted radiation therapy planning for patients receiving 54 Gy to the brain. Int J Radiat Oncol Biol Phys. 2024;119(5):1429-1436. doi:10.1016/j.ijrobp.2024.02.022.
  38. George E, Flagg E, Chang K. Radiomics-based machine learning for outcome prediction in a multicenter phase II study of programmed death-ligand 1 inhibition immunotherapy for glioblastoma. AJNR Am J Neuroradiol. 2022;43(5):675-681. doi:10.3174/ajnr.A7488.
  39. Friesner I, Feng J, Kalnicki S. Machine learning-based prediction of hospitalization during chemoradiotherapy with daily step counts. JAMA Oncol. 2024;10(5):642-647. doi:10.1001/jamaoncol.2024.0014.
  40. Kehayias C, Yan Y, Bontempi D. Prospective deployment of an automated implementation solution for artificial intelligence translation to clinical radiation oncology. Front Oncol. 2023;13. doi:10.3389/fonc.2023.1305511.
  41. Natesan D, Eisenstein E, Thomas S. Health care cost reductions with machine learning-directed evaluations during radiation therapy—an economic analysis of a randomized controlled study. NEJM AI. 2024;1(4). doi:10.1056/aioa2300118.
  42. Wang D, Lee S, Geng H. Interpretable machine learning for predicting pathologic complete response in patients treated with chemoradiation therapy for rectal adenocarcinoma. Front Artif Intell. 2022;5. doi:10.3389/frai.2022.1059033.
  43. Wesdorp N, Zeeuw J, Postma S. Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases. Eur Radiol Exp. 2023;7(1). doi:10.1186/s41747-023-00383-4.
  44. Fremond S, Andani S, Barkey Wolf J. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts. Lancet Digit Health. 2023;5(2). doi:10.1016/S2589-7500(22)00210-2.
  45. Walker G, Awan M, Tao R. Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. Radiother Oncol. 2014;112(3):321-325. doi:10.1016/j.radonc.2014.08.028.
  46. Men K, Geng H, Zhong H. A deep learning model for predicting xerostomia due to radiation therapy for head and neck squamous cell carcinoma in the RTOG 0522 clinical trial. Int J Radiat Oncol Biol Phys. 2019;105(2):440-447. doi:10.1016/j.ijrobp.2019.06.009.
  47. Sher D, Godley A, Park Y. Prospective study of artificial intelligence-based decision support to improve head and neck radiotherapy plan quality. Clin Transl Radiat Oncol. 2021;29:65-70. doi:10.1016/j.ctro.2021.05.006.
  48. Osapoetra L, Dasgupta A, DiCenzo D. Assessment of clinical radiosensitivity in patients with head-neck squamous cell carcinoma from pre-treatment quantitative ultrasound radiomics. Sci Rep. 2021;11(1). doi:10.1038/s41598-021-85221-6.
  49. Mashayekhi M, McBeth R, Nguyen D. Artificial intelligence guided physician directive improves head and neck planning quality and practice uniformity: a prospective study. Clin Transl Radiat Oncol. 2023;40. doi:10.1016/j.ctro.2023.100616.
  50. Sher D, Moon D, Vo D. Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial. Clin Cancer Res. 2023;29(17):3284-3291. doi:10.1158/1078-0432.CCR-23-0334.
  51. Nicolae A, Semple M, Lu L. Conventional vs machine learning-based treatment planning in prostate brachytherapy: results of a phase I randomized controlled trial. Brachytherapy. 2020;19(4):470-476. doi:10.1016/j.brachy.2020.03.004.
  52. McIntosh C, Conroy L, Tjong M. Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nat Med. 2021;27(6):999-1005. doi:10.1038/s41591-021-01359-w.
  53. Sanders J, Kudchadker R, Tang C. Prospective evaluation of prostate and organs at risk segmentation software for MRI-based prostate radiation therapy. Radiol Artif Intell. 2022;4(2). doi:10.1148/ryai.210151.
  54. Thomas C, Dregely I, Oksuz I. Neural network dose prediction for rectal spacer stratification in dose‐escalated prostate radiotherapy. Med Phys. 2022;49(4):2172-2182. doi:10.1002/mp.15575.
  55. Johnsson K, Brynolfsson J, Sahlstedt H. Analytical performance of apromise: automated anatomic contextualization, detection, and quantification of [(18)F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging. 2022;49(3):1041-1051. doi:10.1007/s00259-021-05497-8.
  56. Esteva A, Feng J, van der Wal D. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med. 2022;5(1). doi:10.1038/s41746-022-00613-w.
  57. Spratt D, Tang S, Sun Y. Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid. 2023;2(8). doi:10.1056/EVIDoa2300023.
  58. Ross A, Zhang J, Huang H. External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG/RTOG 9902 phase 3 trial. Eur Urol Oncol. 2024;7(5):1024-1033. doi:10.1016/j.euo.2024.01.004.
  59. Spratt D, Liu V, Jia A. Meta-analysis of individual patient-level data for a multimodal artificial intelligence biomarker in high-risk prostate cancer: results from six NRG/RTOG phase 3 randomized trials. Eur Urol. 2024;86(4):369-371. doi:10.1016/j.eururo.2024.06.019.
  60. Wong J, Fong A, McVicar N. Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning. Radiother Oncol. 2020;144:152-158. doi:10.1016/j.radonc.2019.10.019.
  61. Glaessgen A, Hamberg H, Pihl C. Interobserver reproducibility of percent gleason grade 4/5 in total prostatectomy specimens. J Urol. 2002;168(5):2006-2010. doi:10.1016/S0022-5347(05)64283-8.
  62. Sadimin E, Khani F, Diolombi M, Meliti A, Epstein J. Interobserver reproducibility of percent gleason pattern 4 in prostatic adenocarcinoma on prostate biopsies. Am J Surg Pathol. 2016;40(12):1686-1692. doi:10.1097/PAS.0000000000000714.
  63. Zhu L, Pan J, Mou W. Harnessing artificial intelligence for prostate cancer management. Cell Rep Med. 2024;5(4). doi:10.1016/j.xcrm.2024.101506.
  64. Prostate cancer (Version 1.2025).
  65. Bernier J, Domenge C, Ozsahin M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952. doi:10.1056/NEJMoa032641.
  66. Cooper J, Pajak T, Forastiere A. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-1944. doi:10.1056/NEJMoa032646.
  67. Chai R, Rath T, Johnson J. Accuracy of computed tomography in the prediction of extracapsular spread of lymph node metastases in squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 2013;139(11):1187-1194. doi:10.1001/jamaoto.2013.4491.
  68. Maxwell J, Rath T, Byrd J. Accuracy of computed tomography to predict extracapsular spread in p16-positive squamous cell carcinoma. Laryngoscope. 2015;125(7):1613-1618. doi:10.1002/lary.25140.
  69. Url C, Schartinger V, Riechelmann H. Radiological detection of extracapsular spread in head and neck squamous cell carcinoma (HNSCC) cervical metastases. Eur J Radiol. 2013;82(10):1783-1787. doi:10.1016/j.ejrad.2013.04.024.
  70. Nichols A, Theurer J, Prisman E. Randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma: long-term results of the ORATOR trial. J Clin Oncol. 2022;40(8):866-875. doi:10.1200/JCO.21.01961.
  71. Ferris R, Flamand Y, Weinstein G. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311). J Clin Oncol. 2022;40(2):138-149. doi:10.1200/JCO.21.01752.
  72. Kann B, Aneja S, Loganadane G. Pretreatment identification of head and neck cancer nodal metastasis and extranodal extension using deep learning neural networks. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-32441-y.
  73. Maguire P, Neal C, Hardy S, Schreiber A. Single-arm phase 2 trial of elective nodal dose reduction for patients with locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2018;100(5):1210-1216. doi:10.1016/j.ijrobp.2017.12.277.
  74. Sher D, Pham N, Shah J. Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer. Int J Radiat Oncol Biol Phys. 2021;109(4):932-940. doi:10.1016/j.ijrobp.2020.09.063.
  75. Tsai C, McBride S, Riaz N. Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus-associated oropharyngeal carcinoma treated with definitive chemoradiotherapy. JAMA Oncol. 2022;8(3):364-372. doi:10.1001/jamaoncol.2021.6416.
  76. Chen L, Dohopolski M, Zhou Z. Attention guided lymph node malignancy prediction in head and neck cancer. Int J Radiat Oncol Biol Phys. 2021;110(4):1171-1179. doi:10.1016/j.ijrobp.2021.02.004.
  77. Chen L, Zhou Z, Sher D. Combining many-objective radiomics and 3D convolutional neural network through evidential reasoning to predict lymph node metastasis in head and neck cancer. Phys Med Biol;64(7):75011. doi:10.1088/1361-6560/ab083a.
  78. Dohopolski M, Chen L, Sher D, Wang J. Predicting lymph node metastasis in patients with oropharyngeal cancer by using a convolutional neural network with associated epistemic and aleatoric uncertainty. Phys Med Biol. 2020;65(22). doi:10.1088/1361-6560/abb71c.
  79. Donzé J, Williams M, Robinson E. International validity of the HOSPITAL score to predict 30-day potentially avoidable HOSPITAL readmissions. JAMA Intern Med. 2016;176(4):496-502. doi:10.1001/jamainternmed.2015.8462.
  80. Frizzell J, Liang L, Schulte P. Prediction of 30-day all-cause readmissions in patients hospitalized for heart failure: comparison of machine learning and other statistical approaches. JAMA Cardiol. 2017;2(2):204-209. doi:10.1001/jamacardio.2016.3956.
  81. Nguyen O, Makam A, Clark C. Predicting all-cause readmissions using electronic health record data from the entire hospitalization: model development and comparison. J Hosp Med. 2016;11(7):473-480. doi:10.1002/jhm.2568.
  82. Tevis S, Weber S, Kent K, Kennedy G. Nomogram to predict postoperative readmission in patients who undergo general surgery. JAMA Surg. 2015;150(6):505-510. doi:10.1001/jamasurg.2014.4043.
  83. Hong J, Niedzwiecki D, Palta M, Tenenbaum J. Predicting emergency visits and hospital admissions during radiation and chemoradiation: an internally validated pretreatment machine learning algorithm. JCO Clin Cancer Inform. 2018;2:1-11. doi:10.1200/CCI.18.00037.
  84. Hong J, Eclov N, Stephens S, Mowery Y, Palta M. Implementation of machine learning in the clinic: challenges and lessons in prospective deployment from the system for high intensity evaluation during radiation therapy (SHIELD-RT) randomized controlled study. BMC Bioinformatics. 2022;23(suppl 12). doi:10.1186/s12859-022-04940-3.
  85. Glide-Hurst C, Lee P, Yock A. Adaptive radiation therapy (ART) strategies and technical considerations: a state of the ART review from NRG oncology. Int J Radiat Oncol Biol Phys. 2021;109(4):1054-1075. doi:10.1016/j.ijrobp.2020.10.021.
  86. Jia X, Rong Y, Wu Q. NRG oncology assessment of artificial intelligence for automatic treatment planning in radiation therapy clinical trials: present and future. Int J Radiat Oncol Biol Phys. 2025. doi:10.1016/j.ijrobp.2025.03.045.
  87. Rong Y, Chen Q, Fu Y. NRG oncology assessment of artificial intelligence deep learning-based auto-segmentation for radiation therapy: current developments, clinical considerations, and future directions. Int J Radiat Oncol Biol Phys. 2024;119(1):261-280. doi:10.1016/j.ijrobp.2023.10.033.
  88. Xiao Y, Benedict S, Cui Y. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J Radiat Oncol Biol Phys. 2025;122(2):443-457. doi:10.1016/j.ijrobp.2025.01.006.

Disclosures

Simeng Zhu receives consulting fees from Radformation, grants from Varian Medical Systems and Google, and is the founder and chief executive officer of IntelliOnc outside the submitted work. Austin Sim receives research funding from Novartis. He also receives travel support from and serves as a nonvoting member of the ASTRO Board of Directors outside the submitted work.

Citation

Virk J, Zhu S, Sim AJ, Ma SJ. Recent Trends of Artificial Intelligence in Radiation Oncology: A Narrative Review of Prospective Studies. Applied Radiation Oncology. 2025;14(3):1-13. doi:10.37549/ARO-D-25-0004.